Study Compares Islet Transplantation and Insulin Therapy in Type 1 Diabetes

Understanding Type 1 Diabetes

Type 1 diabetes is a condition characterized by the pancreas’s inability to release insulin, a hormone produced by islet cells that regulates blood sugar levels. Insulin plays a vital role in utilizing sugar from carbohydrates for energy or storing it as glucose for future use. Currently, there is no cure for type 1 diabetes, and treatment options, including insulin therapy, primarily focus on managing blood sugar levels.

Insulin Therapy vs. Islet Transplantation

Insulin therapy is administered through syringes, insulin pens, or pumps to help maintain stable blood sugar levels in individuals with type 1 diabetes. Alternatively, islet transplantation involves the transfer of beta-islet cells from a donor pancreas. This procedure has demonstrated benefits for patients suffering from severe hypoglycemia, aiding in the regulation of blood glucose levels and enhancing the quality of life for those with type 1 diabetes. Typically, islet transplantation occurs after a kidney transplant in patients with type 1 diabetes or end-stage kidney disease to improve kidney function and overall survival. However, the effectiveness of islet transplantation has not been thoroughly evaluated in prior research.

Effectiveness of Islet Transplantation

A recent study conducted by French researchers explored whether islet transplantation could enhance blood sugar level control in type 1 diabetes patients experiencing severe hypoglycemia post-kidney transplantation, in comparison to insulin therapy. The findings were published in The Lancet Diabetes & Endocrinology.

This multicenter, randomized trial included 50 participants with type 1 diabetes, all of whom faced severe hypoglycemia or inadequate blood sugar control after kidney transplantation. Three patients withdrew from the study. The remaining participants were randomly assigned to either immediate islet transplantation or insulin therapy, with the latter group receiving islet transplantation at a later date. After an average follow-up of six months, results indicated that 16 out of 25 patients who underwent immediate islet transplantation achieved a modified beta-score of six or higher, signifying reduced dependence on insulin therapy, while none of the 22 patients in the insulin group reached that score. A beta-score of six or above reflects a successful graft.

Patient Outcomes Following Transplantation

In the immediate islet transplantation group, 24 of the 25 patients retained functioning kidney transplants, and 23 were free from severe hypoglycemia. By the 12-month mark, 63% of the total study participants, or 29 patients, recorded a modified beta-score of six or higher. Consistent with earlier research, improvements in patients’ quality of life were also noted.

The researchers advocated for longer-term studies and follow-up to assess the sustained effectiveness of islet transplantation and potential cost benefits for patients and the healthcare system.

Conclusion

This study suggests that islet transplantation is a safe and effective alternative to insulin therapy. It presents a viable treatment option for type 1 diabetes patients whose previous management strategies have failed to adequately control blood sugar levels.

Reference

Lablanche S, Vantyghem MC, Kessler L, Wojtusciszyn A, Borot S, Thivolet C, Girerd S, Bosco D, Bosson JL, Colin C, Tetaz R, Logerot S, Kerr-Conte J, Renard E, Penfornis A, Morelon E, Buron F, Skaare K, Grguric G, Camillo-Brault C, Egelhofer H, Benomar K, Badet L, Berney T, Pattou F, Benhamou PY; TRIMECO trial investigators. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2018 Jul;6(7):527-537. doi: 10.1016/S2213-8587(18)30078-0.